Characteristics  Switched to RTX  Switched to anti-TNF   P †
Patients, no.  387  941  –
Age, mean ± SD years  58.7 ± 11.2  55.6 ± 12.3  < 0.0001
Female sex, no. (%)  300 (77.5)  757 (80.5)  0.23
Disease duration, mean ± SD years  14.7 ± 10.2  14.0 ± 9.5  0.25
RF positive, no. (%)  242 (64.9)  604 (64.2)  0.06
Comorbidities, no. (%)‡  259 (66.9)  546 (58.0)  0.003
TJC, mean ± SD no.  14.4 ± 8.1  12.5 ± 8.3  < 0.001
SJC, mean ± SD no.  8.7 ± 5.8  8.2 ± 6.1  0.17
ESR, mean ± SD mm/hour  45.0 ± 30.5  43.0 ± 28.5  0.30
CRP level, mean ± SD mg/dl  33.6 ± 35.0  39.7 ± 46.0  0.11
Global health VAS score, mean ± SD  68.5 ± 20.8  63.6 ± 25.1  < 0.001
DAS28, mean ± SD  6.2 ± 1.2  5.9 ± 1.4  < 0.001
Reason for stopping first anti-TNF    0.001
 Inefficacy, no. (%)  190 (49.1)  547 (58.1)
 Adverse events, no. (%)  96 (24.8)  257 (27.3)
 Other/missing, no. (%)  101 (26.1)  137 (14.6)
First anti-TNF therapy
 Etanercept, no. (%)  159 (41.1)  266 (28.3)  < 0.001
 Monoclonal antibody, no. (%)  228 (58.9)  675 (71.7)
Therapy switched to, no. (%)
 Etanercept  –  494 (52.5)
 Infliximab  –  102 (11.0)
 Adalimumab  –  344 (36.5)